Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

Table 2 Transition probabilities: CKD progression and first modelled CV event and OHE probabilities [13]

	CKD1/2	CKD3	CKD4	CKD5 w/o dialysis	Dialysis (acute)	Dialysis (post-acute)	Kidney Transplant (acute)	Kidney Transplant (post-acute)
Transition probabilities CKD progression for patients receiving SoC^a [13]
CKD1/2	0.6696	0.3268	0.3600
CKD3	0.0350	0.8705	0.0931	0.0011	0.0002
CKD4	0.0012	0.1400	0.8043	0.0448	0.0096
CKD 5 w/o dialysis		0.0135	0.0889	0.7143	0.1779		0.0054
Dialysis (acute)						1.0000
Dialysis (post-acute)						0.9921	0.0079
Kidney transplant (acute)								1.0000
Kidney transplant (post-acute)								1.0000

	CKD1/2	CKD3	CKD4	CKD5 w/o dialysis	Dialysis (acute)	Dialysis (post-acute)	Kidney Transplant (acute)	Kidney Transplant (post-acute)
Transition probabilities CKD progression for patients receiving SoC and Finerenone^a [13]
CKD1/2	0.6305	0.3665	0.0030
CKD3	0.0269	0.8770	0.0949	0.0009	0.0002
CKD4	0.0016	0.1548	0.7982	0.0371	0.0083
CKD 5 w/o dialysis		0.0075	0.1267	0.7045	0.1559		0.0054
Dialysis (acute)						1.0000
Dialysis (post-acute)						0.9921	0.0079
Kidney transplant (acute)								1.0000
Kidney transplant (post-acute)								1.0000

	CKD1/2	CKD3	CKD4	CKD5 w/o dialysis	Dialysis (acute)	Dialysis (post-acute)	Kidney Transplant (acute)	Kidney Transplant (post-acute)
Transition probabilities for CV events per CKD stage [13]
Any CV event probability^b	0.0119	0.0127	0.0157	0.0208	0.0208	0.0208	0.0157	0.0157
CV death	0.0062	0.0052	0.0081	0.0157	0.0191	0.0191	0.0081	0.0081
Renal death	0.000	0.000	0.000	0.0001	0.000	0.000	0.000	0.000
Probabilities of OHEs [13]	No CV events				CV event
Subsequent CV event	–				7.32%
Hyperkalaemia leading to hospitalization	0.07%				0.38%
Hyperkalaemia not leading to hospitalization	1.63%				2.35%
New onset of atrial fibrillation	0.35%				2.16%

CKD chronic kidney disease, CV cardiovascular, eGFR estimated glomerular filtration rate, HR hazard ratio, MI Myocardial infarction, OHE Other health events, SoC standard of care, w/o without
^aThe transition probabilities of CKD progression were based on end points that were measured every four months in the FIDELIO-DKD trial with a median follow-up of 2.6 years. For patients that received finerenone, the probability of transitioning to CKD 5 was adjusted with the HR for the onset of eGFR decrease < 15 mL/min/1.73 m² sustained over at least 4 weeks, and the probability of transition to dialysis was adjusted with the HR for progression to dialysis
^bCV events included non-fatal MI, stroke, or hospitalization for heart failure

ISSN: 1475-2840